Patent Issued to Vical and UW

San Diego-based Vical says today it has obtained a patent covering DNA vaccines for the sexually transmitted herpes simplex virus type 2 (HSV-2), the leading cause of genital herpes. Vical (NASDAQ: VICL) says it is in preclinical development of a HSV-2 vaccine in collaboration with the University of Washington School of Medicine, which also is a patent grantee, and the University of Texas Medical Branch. The National Institutes of Health has provided a two-year, $2 million Small Business Technology Transfer grant to develop the vaccine, which is intended for people who have genital herpes caused by HSV-2.

Bruce V. Bigelow was the editor of Xconomy San Diego from 2008 to 2018. Read more about his life and work here. Follow @bvbigelow

Trending on Xconomy